BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics (SRPT)Sarepta Therapeutics2026-06-25 13:46 ESTCompany update

– Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.

Open original release

Related news

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

View all latest news

Sarepta Therapeutics

Sarepta Therapeutics is a genetic medicines company focused on neuromuscular disease, with investors watching how its RNA and gene-therapy programs translate into durable clinical and commercial value.

Recent company news

SRPTSarepta Therapeutics2026-06-26 08:50 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-06-26 08:50 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SRPTSarepta Therapeutics2026-06-26 08:50 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-06-26 08:50 EST

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

SRPTSarepta Therapeutics2026-06-26 08:50 EST

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States